JULY 14, 2026 AT 01:15 PM

Biogen (BIIB) says Phase 2 CELIA data presented at AAIC demonstrate meaningful clinical outcomes and robust tau reduction with diranersen in early Alzheimer’s disease

Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.

Open Dashboard

#BIOGEN IDEC INC#BIIB.US#EQUITIES#EU SESSION#US SESSION#BIOTECHNOLOGY#BIOTECHNOLOGY (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#NASDAQ 100 INDEX#BIOGEN INC#BIIB#US EQUITIES